AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10210264
Drug: NXX-066 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXX-066 60 mg BID
Trial: 10210264
Drug: NXX-066 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXX-066 70 mg BID
Trial: 10210264
Drug: NXX-066 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXX-066 80 mg BID
Trial: 21486974
Drug: 4-drug fixed-dose
RxNorm normalized name: 4-MIXED TRACE ELEMENTS INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug fixed-dose combination (FDC) regimen (rifampicin, isoniazid, pyrazinamide, ethambutol)
Trial: 21486974
Drug: Separate drugs
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate drugs regimen
Trial: 21486974
Drug: 4-drug fixed-dose
RxNorm normalized name: 4-MIXED TRACE ELEMENTS INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug fixed-dose combination (FDC) regimen
Trial: 7481864
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus doxorubicin plus escalating doses of paclitaxel
Trial: 6290980
Drug: pirprofen 200
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pirprofen 200 mg
Trial: 6290980
Drug: pirprofen 400
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pirprofen 400 mg
Trial: 6290980
Drug: ketoprofen 150
RxNorm normalized name: ketoprofen 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoprofen 150 mg
Trial: 31832778
Drug: Intravenous triglyceride
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous triglyceride (TG) infusion
Trial: 24691771
Drug: Group-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based exercise program (twice a week for 3 months)
Trial: 17650794
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of prednisone and cyclophosphamide (CTX) plus Chinese medicine Langchuang Recipe after gamma‐globulin treatment
Trial: 12037371
Drug: 6 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mmol/l sodium hexafluorosilicate‐calcium chloride‐based two‐solution fluoride rinse
Trial: 12037371
Drug: 12 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mmol/l sodium fluoride rinse
Trial: 7608262
Drug: Naltrexone (Nal;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (Nal; 100 mg/day) during estradiol (E2) and progesterone (P) administration (Nal 1)
Trial: 7608262
Drug: Naltrexone (Nal;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (Nal; 100 mg/day) during pulsatile GnRH administration (Nal 2)
Trial: 7608262
Drug: Pulsatile GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile GnRH administration (10 micrograms/pulse, iv, every 90 min)
Trial: 29426436
Drug: Topical silicone
RxNorm normalized name: silicones Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silicone gel (Dermatix Ultra) applied to one scar for 2 months
Trial: 10405234
Drug: Sulpiride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (50 mg every 8 hours for 24 hours)
Trial: 10405234
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg every 8 hours for 24 hours)
Trial: 2180390
Drug: Cephalothin 2
RxNorm normalized name: cephalothin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin 2 g X 4 on the day of operation
Trial: 2180390
Drug: Methicillin 1
RxNorm normalized name: methicillin 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methicillin 1 g X 4 on the day of operation
Trial: 27329448
Drug: Darapladib (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib (selective Lp-PLA2 inhibitor)
Trial: 20053788
Drug: Ariva/Stonewall (smokeless
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ariva/Stonewall (smokeless tobacco lozenges)
Trial: 15817428
Drug: Hydrocortisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (100 mg loading dose followed by 0.18 mg/kg/h continuous infusion for 6 days)
Trial: 10906641
Drug: Sunscreen alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen alone (gel)
Trial: 10906641
Drug: Sunscreen alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen alone (cream)
Trial: 8814740
Drug: Helium ion
RxNorm normalized name: Helium
DrugBank: Helium (DB09155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Helium ion therapy
Trial: 8814740
Drug: 125I radioactive
RxNorm normalized name: fibrinogen (125I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I radioactive plaque therapy
Trial: 8814740
Drug: Helium ion
RxNorm normalized name: Helium
DrugBank: Helium (DB09155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Helium ion therapy and 125I brachytherapy
Trial: 31627889
Drug: Colloid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid group (HES solution 750 ml)
Trial: 31627889
Drug: Crystalloid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid group (LR solution 2825 ml)
Trial: 29430176
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of alpha 1 antitrypsin (AAT)
Trial: 26444030
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continuing for 24 h after surgery.
Trial: 20964833
Drug: Sulphasalazine and
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine and hydroxychloroquine (treatment A)
Trial: 20964833
Drug: Infliximab (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (treatment B)
Trial: 17347185
Drug: Phenylephrine 100
RxNorm normalized name: phenylephrine 100 mcg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 100 microg ml‐1
Trial: 17347185
Drug: Ephedrine 4.5
RxNorm normalized name: chlorpheniramine-pseudoephedrine 4.5 mg-75 mg/5 mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 4.5 mg ml‐1
Trial: 12077742
Drug: High-isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone soy diet (73 mg/d isoflavone)
Trial: 12077742
Drug: Low-isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-isoflavone soy diet (10 mg/d isoflavone)
Trial: 2911850
Drug: Short-term doxorubicin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term doxorubicin infusion (10 mg/m2/day for 5 days)
Trial: 2911850
Drug: Long-term doxorubicin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term doxorubicin infusion (3 mg/m2/day for 5-104 days)
Trial: 2911850
Drug: Short-term doxorubicin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term doxorubicin infusion
Trial: 2911850
Drug: Long-term doxorubicin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term doxorubicin infusion
Trial: 2911850
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of doxorubicin
Trial: 31424962
Drug: Herbal extracts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal extracts (mangosteen, Lithospermum officinale, Tribulus terrestris L., Houttuynia cordata Thunb)
Trial: 27489211
Drug: TV‐1106 (7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV‐1106 (7.5, 15, 50, and 100 mg)
Trial: 27489211
Drug: TV‐1106 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV‐1106 (7.5 and 15 mg)
Trial: 27489211
Drug: TV‐1106 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV‐1106 (50 and 100 mg)
Trial: 14679674
Drug: Low-dose perindopril/indapamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose perindopril/indapamide (2 mg and 0.625 mg daily)
Trial: 14679674
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment of atenolol (50 mg) then losartan (50 mg) then amlodipine (5 mg)
Trial: 14679674
Drug: Step-by-step strategy
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-by-step strategy of valsartan (40 mg then 80 mg then 80 mg plus hydrochlorothiazide 12.5 mg)
Trial: 10989766
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe daily)
Trial: 10989766
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe twice weekly)
Trial: 10989766
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe once weekly)
Trial: 10989766
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no iron supplement)
Trial: 1534832
Drug: Long-term sodium
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term sodium restriction (daily sodium intake reduced to less than 70 mmol)
Trial: 31782367
Drug: Fresh pomegranate
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh pomegranate juice (1.5 mL kg‐1)
Trial: 19479153
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of 0.25% bupivacaine
Trial: 17229221
Drug: Enteral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutritional therapy (EN group)
Trial: 17229221
Drug: Non-nutritional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nutritional therapy (non-EN group)
Trial: 15535487
Drug: Pyridostigmine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 5 minutes after rocuronium administration
Trial: 15535487
Drug: Pyridostigmine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 1% twitch height (T1) recovery
Trial: 15535487
Drug: Pyridostigmine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 25% twitch height (T25) recovery
Trial: 11555061
Drug: Preintervention treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preintervention treatment with parenteral antibiotics (PA) when PA were recommended by the guidelines (n = 127)
Trial: 11555061
Drug: Preintervention treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preintervention treatment with oral antibiotics (OA) when OA were indicated by the guidelines (n = 99)
Trial: 11555061
Drug: Postintervention treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postintervention treatment with PA and OA according to the guidelines
Trial: 10021958
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml saline
Trial: 29234746
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 6 mm long implants
Trial: 12010156
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm long implants
Trial: 26323921
Drug: Nimotuzumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab (200 mg) with docetaxel (60 mg/m2) and carboplatin (AUC = 5)
Trial: 26323921
Drug: Chemotherapy (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (docetaxel 60 mg/m2 and carboplatin AUC = 5)
Trial: 26323921
Drug: Nimotuzumab with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab with chemotherapy
Trial: 23447123
Drug: Insulin administered
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin administered according to the customary insulin:carbohydrate ratio
Trial: 21672597
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from 9-10 mg ISO tar yield cigarette to 4 mg ISO tar yield cigarette
Trial: 21672597
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from 4-6 mg ISO tar yield cigarette to 1 mg ISO tar yield cigarette
Trial: 19929644
Drug: Diaphragm and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm and lubricant gel intervention
Trial: 15679256
Drug: Targeted drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted drugs in combination with ionizing radiation
Trial: 10678543
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor ramipril (5 mg/day for 3 weeks)
Trial: 10678543
Drug: AT1B losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1B losartan (50 mg/day for 3 weeks)
Trial: 10678543
Drug: Control L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control L-arginine infusion
Trial: 10678543
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor ramipril and AT1B losartan
Trial: 9549634
Drug: Enalapril/Diltiazem ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril/Diltiazem ER with other agents (n = 79)
Trial: 3484691
Drug: Digoxin, 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin, 0.375 mg/day, loaded with doubled doses on days 1 and 2, for 14 days.
Trial: 3484691
Drug: Bepridil, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil, 300 mg/day, loaded with 900 mg on day 8.
Trial: 3484691
Drug: Concurrent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent dosing of digoxin and bepridil.
Trial: 3484691
Drug: Concurrent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent dosing of both drugs.
Trial: 26092233
Drug: lipegfilgrastim 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipegfilgrastim 6 mg
Trial: 19896200
Drug: Re-ChORD (integrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-ChORD (integrative treatment program including medication management, interpersonal psychotherapy, and occupational therapy)
Trial: 8918674
Drug: Routine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine administration of rG‐CSF on the 6th day after BEP chemotherapy (group A)
Trial: 8918674
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of rG‐CSF after granulocytopenia of 1,500/mm3 had developed (group B)
Trial: 8918674
Drug: BEP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEP chemotherapy
Trial: 1747882
Drug: Fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride toothpaste with sodium monofluorophosphate, calcium glycerophosphate supplement, and calcium carbonate abrasive
Trial: 1747882
Drug: Fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride toothpaste with sodium monofluorophosphate and sodium fluoride, calcium glycerophosphate supplement, and calcium carbonate abrasive
Trial: 27909081
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) monotherapy
Trial: 28763316
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (5 mg/kg) coadministered with neostigmine (25 μg/kg) and atropine (15 μg/kg)
Trial: 28763316
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline coadministered with neostigmine (25 μg/kg) and atropine (15 μg/kg)
Trial: 23468553
Drug: Maternal lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal lipid-based nutrient supplements (LNS) during lactation
Trial: 16490808
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) 20 mg for 7 days with CyA 100 mg coadministered on day 7
Trial: 16490808
Drug: CyA 100
RxNorm normalized name: Sangcya 100mg/ml Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA 100 mg alone
Trial: 7225165
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg tid for 4 weeks
Trial: 7225165
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg tid for 9 weeks
Trial: 7225165
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg tid for 9 weeks in 10 subjects with lipoprotein cholesterol fractionation
Trial: 30778571
Drug: EOD1 (Essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOD1 (Essential oil blends and Vitamin D3; 50 μg 25‐OH‐D3/kg diet, 15 mg CRINA Poultry/kg diet)
Trial: 30778571
Drug: EOD2 (Essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOD2 (Essential oil blends and Vitamin D3; 69 μg 25‐OH‐D3/kg diet, 30 mg CRINA Poultry/kg diet)
Trial: 30778571
Drug: EOD3 (Essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOD3 (Essential oil blends and Vitamin D3; 138 μg 25‐OH‐D3/kg diet, 50 mg CRINA Poultry/kg diet)
Trial: 29851824
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg of rocuronium intravenously (group L)
Trial: 29851824
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg of rocuronium (group C)
Trial: 24128379
Drug: Opioid substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid substitution therapy (OST)
Trial: 22292061
Drug: Intervention by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention by clinical pharmacists including answering questions of physicians and nurses, giving advice on treating patients, checking prescriptions and patient counseling at discharge.
Trial: 17516484
Drug: Entacapone (ENT),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (ENT), 3 to 5 times daily
Trial: 17516484
Drug: Cabergoline (CBG),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (CBG), titrated to a maximum of 6 mg/d
Trial: 12390384
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg intravenously twice daily followed by oral ranitidine 150 mg twice daily for 5 years
Trial: 10090428
Drug: Sparfloxacin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 400 mg loading dose on day 1, followed by 200 mg once daily for 10 days
Trial: 31153360
Drug: Dexmedetomidine 0
RxNorm normalized name: dexmedetomidine 0.12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0 mcg/kg (group 1)
Trial: 31153360
Drug: Dexmedetomidine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.3 mcg/kg (group 2)
Trial: 31153360
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 mcg/kg (group 3)
Trial: 31153360
Drug: Dexmedetomidine 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.9 mcg/kg (group 4)
Trial: 24448227
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg daily for 24 months
Trial: 24448227
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 24 months
Trial: 17263650
Drug: TPV/r 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPV/r 500 mg/100 mg
Trial: 17263650
Drug: TPV/r 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPV/r 500 mg/200 mg
Trial: 17263650
Drug: TPV/r 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPV/r 750 mg/200 mg
Trial: 12473477
Drug: Ampicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (1 g)
Trial: 12473477
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mL sterile water)
Trial: 9666830
Drug: 5 times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 times weekly narrow-band TL-01 UVB phototherapy